Drug Profile
Research programme: topoisomerase inhibitors - Evolva/Topotarget
Latest Information Update: 10 Jul 2009
Price :
$50
*
At a glance
- Originator Evolva Biotech; TopoTarget
- Class Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 10 Jul 2009 No development reported - Preclinical for Cancer in Denmark (unspecified route)
- 10 Jul 2009 No development reported - Preclinical for Cancer in Switzerland (unspecified route)
- 07 Mar 2007 Preclinical trials in Cancer in Denmark (unspecified route)